tbuckley/cabot-search huggingface dataset:
PTH-109 Real Life Data on Sofosbuvir/Ledipasvir + Ribavirin for 12 Weeks in Genotype 3 Patients in The North East of Scotland
Authors: P Dundas, A Fraser, S English, L McLeman
Journal: Gut (2016)

<h3>Introduction</h3> There are robust data from clinical trials supporting the use of the combination of Sofosbuvir and Ledipasvir (sof/ledip) in patients with Genotype 1 HCV infection with expected SVR rates of &gt;90%. Data on the success rates of this combination for the treatment of patient with Genotype 3 infection are less robust. Our aim was to examine the SVR rates when using this combination in a “real life’ setting in patients with Genotype 3 infection. <h3>Methods</h3> Local guidelines from December 2014 to November 2015 advised the use of the combination of sof/ledip along with ribavirin for 12 weeks for patients with Genotype 3 HCV infection who were interferon intolerant or ineligible. During this period, data was collected prospectively on all patients commenced this regimen. Fibrosis F3 was defined as fibroscan &gt;9 kPa, cirrhosis was defined as a fibroscan &gt;12.5 kPa or confirmed on liver biopsy. <h3>Results</h3> In total 26 patients with genotype 3 infection received treatment with sof/ledip plus ribavirin for 12 weeks. Of the 26 patients, 21 (81%) were male. The average age was 53 (range 38–68). Mean fibroscan score was 18.7 kPa (range 4.8–63.9). Table 1 describes the fibroscan score distribution. The majority (17/26) (65%) of patients were treatment naive. Opiate substitution therapy was prescribed in 5/26 (19%). SVR 4 data is available in 25 patients (22/25, 88%) and SVR 12 available in 21 patients (17/21, 81%). Figure 1 shows SVR data for those with and without cirrhosis, SVR was 100% in those without cirrhosis. One patient died of end stage liver disease at week 3 on treatment but all others have completed the prescribed course of treatment. One patient is HCV RNA negative at the end of treatment but not yet 4 weeks post treatment. The 3 patients who did not achieve SVR 12 were all cirrhotic with a history of hepatic decompensation, 2 treatment naive and 1 treatment experienced. Intention to treat analysis of SVR 12 for all patients will be available by the time of presentation. <h3>Conclusion</h3> There are limited options for all oral therapy to treat patients with Genotype 3 HCV infection. Our data demonstrates that the combination of sof/ledip with ribavirin is well tolerated with few side effects. All patients without cirrhosis completed the planned treatment regimen and obtained viral clearance. As a result of emerging data and our experience of a lower SVR rate in patients with cirrhosis, our guideline has been adapted to using alternative therapies as first line in patients with Genotype 3 infection and cirrhosis. We keep our guidelines for the treatment of patients without cirrhosis under review while awaiting analysis of the full dataset and further drug developments <h3>Disclosure of Interest</h3> None Declared
Stem-Cell Transplantation in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia in First Complete Remission: A Prospective Multicenter Trial Comparing Haploidentical Donors with Identical Sibling Donors
Authors: Yu Wang, Wu Depei, Qifa Liu, Lan-Ping Xu, Xiao-Hui Zhang, Xiao-Jun Huang
Journal: Blood (2015)
Transcription Factor BACH2 Inhibits AP1 Proteins JunB and FosL1 in Umbilical Cord Blood (UCB) CD4+ T-Cells.
Authors: Mathew L. Lesniewski, Laura R. Fanning, Margeret Kozik, Richard P. Weitzel, Yeal Hegerfeldt, Ramasamy Sakthivel, Mary J. Laughlin
Journal: Blood (2006)
THU0466 Osteoporosis-Related Ankle Fracture: Should We Consider It?
Authors: Ά. Prior-Español, S. Rodríguez-Muguruza, A. Florido, I. Casas, J. Sanint, Y. García-Mira, M. Martínez-Morillo, L. Mateo, J. Cañellas, X. Tena, J.A. Hernandez-Hermoso, A. Olivé, S. Holgado
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Osteoporosis is defined as a systemic skeletal disease characterized by low mineral density and microarchitectural changes in the bone which increase its fragility and fracture risk. Ankle fracture is one of the most common fractures; however the relation with osteoporosis is still being debated. The diagnosis and treatment of osteoporosis is not always adequate. <h3>Objectives</h3> To determine the relation of ankle fractures to osteoporosis <h3>Methods</h3> Retrospective study 2008–2014. Center: Tertiary academic hospital with a referral area of 850,000 inhabitants. The medical charts, bone mineral density (BMD), radiographs and electronic data bases of patients with ankle fracture were reviewed. Demographic data (age, gender), BMD, mechanism of injury (high or low energy trauma), fracture pattern (single malleolus, bimaleollar and trimalleolar fracture) and treatment of fracture and osteoporosis were collected. Patients were divided into younger age (≤60years) and older age (&gt;60 years) groups. <h3>Results</h3> A total of 299 patients with ankle fractures were included. The mean age was 49.5 years (DS 26.5). There were 131 (43.8%) male and 168 (56.2%) female patients. Among these patients, 84 (28.1%) were in the older age group (74% female and 26% male) and 216 (72.2%) were in the younger age group (51% male and 49% female). Bimaleolar fracture was the most common pattern in both groups (62.7% and 50.5%). Proportion of low energy trauma and conservative treatment was higher in elderly group compared to younger group (63.9% vs 38%, p 0.002/20.5% vs 8.3%; p 0.003). Of note 34 (11.7%) of patients underwent a dual-energy X-ray absorptiometry (DXA): 17 (50%) in the elderly group and 17 (50%) in younger (82% were older than 50 years). In the older group only 1 (5.9%) patient had a normal BMD, 8 (47.1%) had osteopenia and 8 (47.1%) had osteoporosis. Compared with younger patients, osteoporosis was more frequent in older group (10.8% vs 1.4%; p&lt;0.005). Older patients had a higher proportion of new fractures than younger (23.8% vs 12.6%; p 0.016), between 3 and 60 months after the ankle fracture. The new fractures were: 9 Colles9, 4 vertebral, 4 hip and 3 in other location. <h3>Conclusions</h3> Ankle fracture was more common in females in the older group. DXA was performed in a very low percentage of cases. The features of ankle fractures and the higher ratio of new fractures in the older group suggest a possible link with osteoporosis. Patients with ankle fracture should be studied in order to diagnose osteoporosis. These patients may have a benefit of treatment. <h3>Disclosure of Interest</h3> None declared
FRI0351 Influences of Hydroxychloroquine Use on The Risk of Cancers in Patients with Sjögren's Syndrome: Propensity Score Matched Landmark Analysis
Authors: T.-T. Chuang, C.-F. Kuo
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Hydroxychloroquine is a disease-modifying anti-rheumatic drug for patients with Sjögren9s syndrome who have an increased risk of malignancies, particularly lymphoma. Inhibition of systemic inflammation and autophagy by hydroxychloroquine has been linked to antineoplastic effects but there is a lack of evidence on the effect of hydroxychloroquine on the risk of cancers in patients with Sjögren9s syndrome. <h3>Objectives</h3> This study aimed to explore the effect of hydroxychloroquine on the risk of cancers in patients with Sjögren9s syndrome. <h3>Methods</h3> We compared cancer incidence in incident patients with Sjögren9s syndrome who received hydroxychloroquine for at least 6 months within one year or three years to those did not using the Taiwan National Health Insurance Research Database. Landmark analysis was used to account for immortal time bias and propensity score matching was used to control for potential effects of known confounders. <h3>Results</h3> Of 4,262 Sjögren9s syndrome patients was identified between 2000 to 2005, we included 4,175 patients who were alive and did not have cancer at one year from initial diagnosis of Sjögren9s syndrome. The propensity score matched 1,141 patients who exposed to 6 months of hydroxychloroquine prescription on the date 1 year from the initial diagnosis and 1,141 patients who was not exposed to hydroxychloroquine. The median follow year was 6 years from one-year landmark. There were 71 hydroxychloroquine users and 56 non-hydroxychloroquine users had cancer during the follow-up. The hazard ratio for cancer was 1.31 (95% confidence interval [CI], 0.92–1.86) in the one year landmark analysis. We further conducted three-year landmark analysis and 6-month hydroxychloroquine exposure was associated with a hazard ratio of 1.33 (95% CI, 0.98–1.81) in the three-year landmark analysis between hydroxychloroquine users and non-hydroxychloroquine users, was 1.31 (0.92–1.86) in the one landmark analysis. There was no difference in overall survival based on Kaplan-Meier estimates between hydroxychloroquine user and non-users in both the one-year (log-rank test p=0.15) and three-year landmark analysis (log-rank test p=0.09). <h3>Conclusions</h3> This propensity score matched landmark analysis in a population of incident patients with Sjögren9s syndrome in Taiwan found a neutral effect of 6-month hydroxychloroquine treatment early in the clinical course on the risk of cancer, but whether a higher dose or an longer exposure to hydroxychloroquine could influence the risk of cancer remains to be determined. <h3>Disclosure of Interest</h3> None declared
Shadow of the law in cases of avoidable harm
Authors: Liam J Donaldson
Journal: BMJ (2016)

The law's intervention in patient safety can be haphazard and inconsistent 

“Jail time for a medical error.” This was the headline of Bob Wachter’s patient safety blog about the Ohio pharmacist Eric Cropp.1 When Cropp’s professional colleagues saw him clad in an orange jumpsuit in a prison visiting room, they knew it could have been them. A pharmacy technician mistakenly mixed chemotherapy drugs with 23% saline, not 0.9%. A child died. It was a rushed, understaffed day, with computer failures. Cropp’s supervisory check failed to spot the error. He was convicted of manslaughter in 2009.

A junior doctor in Nottingham, England, was jailed in 2003 for killing a cancer patient who was given vincristine through the wrong route. The investigator had identified some 40 systems failures,2 yet individual accountability won the day in court. It had happened before in the UK in similar circumstances, but other doctors had been quietly counselled.

A look back from 2005 at the doctors charged with manslaughter in …
A Study Comparing Dosing Regimens and Efficacy of Subcutaneous to Intravenous Azacitidine (AZA) for the Treatment of Myelodysplastic Syndromes (MDS).
Authors: Mikkael A. Sekeres, Jaroslaw P. Maciejewski, David W. Donley, David L. Grinblatt, Mohit Narang, James M. Malone, Rami S. Komrokji, Alan F List, Julie G. Baker, David A. Sweet, Kristen A. Sullivan
Journal: Blood (2009)
PTU-112 Proton Pump Inhibitors – A Risk for Micronutrient Deficiency. But Are We Looking Out for This?
Authors: TM El Menabawey, S Dluzewski, S Phillpotts, R Preedy, K Besherdas
Journal: Gut (2016)

<h3>Introduction</h3> Proton pump inhibitors (PPIs) have long been established as an effective evidence based therapy for many upper gastrointestinal diseases including peptic ulcer disease, gastro-oesophageal reflux disease, oesophagitis and dyspepsia. However, nonjudicious use of PPIs creates both preventable financial as well as medical concerns. There are several studies that point to potential micronutrient deficiencies including iron, vitamin B12, magnesium and calcium as a consequence of long-term PPI use. While these risks are considered to be relatively low in the general population, they may be notable in elderly and malnourished patients on PPIs. Although high quality evidence for the true burden of deficiency is scarce, clinicians should have an awareness of the potential for these side effects in patients, particularly those on long-term PPIs. We hypothesised that despite increasing evidence of micronutrient deficiency in patients on long term PPIs, this is not assessed in clinical practice. <h3>Methods</h3> A single centre, retrospective analysis of all patients on long term PPIs usage in a large NHS North London trust was performed. Patients with Barrett’s oesophagus were used as a database of patients on long term PPIs. Their names were identified from the Unisoft endoscopy reporting system as undergoing endoscopic surveillance for Barrett’s. We reviewed their electronic patient records to see if they had ever had their indices for B12, ferritin or magnesium tested whilst they had been undergoing outpatient clinical review. <h3>Results</h3> Of 41 patients identified, 38 (92.7%) had not had serum magnesium checked in the last 12 months including 15 (36.59%) who had never had it checked. 32 (78.1%) had not had serum ferritin or B12 checked in the past 12 months. Including 9 (21.95%) whom had never had it checked. The median magnesium level was low (0.77, range 0.76–0.89). The median ferritin was normal (106, range 13–196). There was one incidence of B12 deficiency (2.44% all patients, 31.3% of all those tested). Median serum B12 was normal (351, range 10.6–645). <h3>Conclusion</h3> Despite evidence in the literature of an association between long term PPI use and micronutrient deficiency, the investigation for this by clinicians in a high-risk group was poor and inconsistent. Even in this small cohort, magnesium and B12 deficiency was detected. We would recommend that clear guidance from the British Society of Gastroenterology and other national Gastroenterology bodies on micronutrient monitoring in patients on long term PPIs is required. This may improve screening of micronutrients in long term PPI usage and identify those requiring supplementation. <h3>Disclosure of Interest</h3> None Declared
Late Effects and Quality of Life of Survivors of Childhood Hematologic Malignancies Treated Mainly during 80’s in Japanese Group Study.
Authors: Takeji Matsushita, Arata Watanabe, Noriko Satou, Atsushi Kikuta, Susumu Iizuka, Takahiro Uehara, Keiko Asami, Hideo Mugishima, Yasuhiko Kaneko, Toshinori Hori, Shigeru Ohta, Tomoko Kuno, Chikara Watanabe, Nobuyuki Hyakuna, Junichi Ueyama, Keiko Nomura, Kazuhiro Kokawa, Tsuyako Iwai, Jun-ichi Mimaya, Shouichi Koizumi, Masahito Tsurusawa
Journal: Blood (2005)
Full Donor Chimerism in Both Plasma and Mononuclear Cell after Haematopoietic Stem Cell Transplant (HSCT) at D28 Is Predictive of Acute Graft-Versus-Host Disease but Not Disease Relapse or Graft Failure.
Authors: Shing Yan Ma, Wing Yan Au, Albert K.W. Lei, Eric Tse, Chor Sang Chim, Raymond Liang, Yok Lam Kwong
Journal: Blood (2004)
AB0657 Discontinuation of Anti-TNF Therapy in Patients with Axial Spondyloarthritis in Clinical Practice: Prevalence and Causes
Authors: E. Moral, C. Plasencia, V. Navarro-Compán, D. Pascual Salcedo, T. Jurado, C. Tornero, A. Pierens, M.B. Paredes, P. Bogas, I. Monjo, E. Martin Mola, A. Balsa
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The majority of patients with axial spondyloarthritis (SpA) response to anti-TNF therapy. However, discontinuation of this therapy due to different reasons is still a relevant problem. Currently, there is not enough data to know exactly which is the prevalence and causes of interruption of anti-TNF therapies in clinical practice. <h3>Objectives</h3> First, to evaluate the frequency and causes of discontinuating adalimumab or infliximab as the first anti-TNF in patients with axial SpA in clinical practice. Second, to investigate the influence of anti-drug antibodies (ADA) on these causes. <h3>Methods</h3> A total of 326 patients with axial SpA who had received adalimumab (34%) or infliximab (66%) as a first anti-TNF therapy were included in this retrospective, observational study performed in a tertiary hospital. Disease activity (BASDAI, ASDAS, CRP and ESR) was measured before starting anti-TNF therapy, after 6 months and when interrupting the therapy to assess properly whether the reason for discontinuation was primary or secondary failure. Serum drug levels and/or ADA were measured at 6 months visit and at the end of anti-TNF treatment. <h3>Results</h3> A total of 99 (30.4%) patients discontinued treatment. Mean (SD) under anti-TNF therapy until discontinuation was 2.5 (2.9) years. Characteristics of these patients when initiating anti-TNF therapy are shown in Table 1. The reason to interrupt treatment was: primary failure in 22.2%, secondary failure in 36.4%, side effects 32.3%), and other reasons in 9.1%. Serum drug levels and ADA were available in 83 patients. In most patients with ADA positive (14/17), the reason for discontinuation was secondary failure. Out of those patients who discontinued due to secondary failure, 38.9% had ADA positive. <h3>Conclusions</h3> In our cohort of patients with axial SpA treated with adalimumab/infliximab, 30% of patients discontinued anti-TNF therapy. The main reason to discontinue treatment was secondary failure, which was related to the presence of ADA in almost 40% of patients. <h3>Disclosure of Interest</h3> E. Moral Grant/research support from: Funded by an unrestricted medical grant from Pfizer, C. Plasencia: None declared, V. Navarro-Compán: None declared, D. Pascual Salcedo: None declared, T. Jurado: None declared, C. Tornero: None declared, A. Pierens: None declared, M. B. Paredes: None declared, P. Bogas: None declared, I. Monjo: None declared, E. Martin Mola: None declared, A. Balsa: None declared
AB0562 Demographic Characteristics and Distribution of The Vasculitides Frequencies: A Real- Life Experience of Vasculitis Center from Eastern Mediterranean
Authors: O. Karadag, A. Erden, E. Bilgin, E.D. Batu, B. Armagan, A. Sarı, E. Fırat, Z.S. Arıcı, A.O. Uyaroğlu, E. Seyhoglu, E.C. Bolek, U. Kalyoncu, A. Akdoğan, S.A. Bilgen, S. Kiraz, I. Ertenli, S. Ozen
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Vasculitides are a heterogeneous group of diseases. The distribution of the type of vasculitis changes not only with age and sex but according to the geographic area as well. The prevalence of each vasculitis is important in guiding the local medical education and raising awareness of doctors and policy makers etc. <h3>Objectives</h3> This study is aimed to present the distribution of vasculitides in the Pediatric and Adult Vasculitis patient Groups. <h3>Methods</h3> Hacettepe University is one of the main referral centers in the country. Executive committee of our Vasculitis center consist of physicians from Pediatric and Adult Rheumatology, Nephrology, Radiology and Pathology Departments. Multidisciplinary approach improves management of our patients. All patients starting from October 2014 have been included and defined according to the 2012 revised Chapel Hill nomenclature criteria. <h3>Results</h3> A total of 882 patients had been newly diagnosed/followed in this period. 205 (23.2%) of them were pediatric patients. The leading vasculitis among adult patients was Behcet9s Disease whereas in pediatric patients it was HSP (Figure). More than half of the adult Behcet9s patients (58.4%) had uveitis/neurologic/vascular involvement. Takayasu arteritis was more frequent than giant cell arteritis among the adult patients. There was a female predominance in patients with large vessel vasculitis. Granulomatous polyangiitis was the most common small vessel vasculitis in adults. Finally 23 adult cases of Immunglobulin G4 related disease have been seen. <h3>Conclusions</h3> We describe the demographic characteristics and distribution of vasculitides in the eastern Mediterranean. Behcet9s disease has a high frequency as expected. Also Takayasu arteritis is more frequent than Giant cell arteritis. Microscopic polyangiitis is very rare. Among children Kawasaki was less and Behçet disease markedly more when compared to western Europe figures. The observed differences may be due to genetic modifiers or environmental factors. <h3>Disclosure of Interest</h3> None declared
Chronic adiponectin deficiency leads to Alzheimer’s disease-like cognitive impairments and pathologies through AMPK inactivation and cerebral insulin resistance in aged mice
Authors: Roy Chun-Laam Ng, On-Yin Cheng, Min Jian, Jason Shing-Cheong Kwan, Philip Wing-Lok Ho, Kenneth King-Yip Cheng, Patrick Ka Kit Yeung, Lena Lei Zhou, Ruby Lai-Chong Hoo, Sookja Kim Chung, Aimin Xu, Karen Siu-Ling. Lam, Koon Ho Chan
Journal: Molecular Neurodegeneration (2016)

Insulin resistance is the major pathogenesis underlying type 2 diabetes mellitus (T2DM) and these patients have doubled risk of Alzheimer's disease (AD). Increasing evidence suggests that insulin resistance plays an important role in AD pathogenesis, possibly due to abnormal GSK3β activation, causing intra- and extracellular amyloid-beta (Aβ) accumulation. Adiponectin (APN) is an adipokine with insulin-sensitizing and anti-inflammatory effects. Reduced circulatory APN level is associated with insulin resistance and T2DM. The role of APN in AD has not been elucidated. In this study, we aim to examine if adiponectin deficiency would lead to cerebral insulin resistance, cognitive decline and Alzheimer's-like pathology in mice.
Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study
Authors: Shyamala C. Navada, Rosalie Odchimar-Reissig, E. Premkumar Reddy, James F Holland, Francois Wilhelm, Lewis R. Silverman
Journal: Blood (2012)
A Randomized Trial Comparing Individualized Vs. Non-Individualized Treatment for Elderly Acute Myeloid Leukemia: JALSG GML200 Study
Authors: Atsushi Wakita, Shigeki Ohtake, Satoru Takada, Fumiharu Yagasaki, Hirokazu Komatsu, Yasushi Miyazaki, Koumei Kubo, Yukihiko Kimura, Akihiro Takeshita, Yoko Adachi, Hitoshi Kiyoi, Takuhiro Yamaguchi, Minoru Yoshida, Kazunori Ohnishi, Shuichi Miyawaki, Tomoki Naoe, Ryuzo Ueda, Ryuzo Ohno
Journal: Blood (2008)
The History of 34 Errors Identified in 874 Patients Analyzed at Weekly Clinical-Pathological Meetings in Two Institutions over 22 Years (1982–2004).
Authors: Evarist Feliu, Blanca Xicoy, Maria Rozman, Fuensanta Milla, Josep-Lluis Aguilar, Jose-Luis Mate, Jose-Lluis Vives, Josep-Maria Ribera, Elias Campo, Jordi Junca, Neus Villamor, Isabel Granada, Dolors Colomer, Jose-Tomas Navarro, Ciril Rozman
Journal: Blood (2004)
Low Relapse without Excessive Transplant-Related Mortality Following Allogeneic Stem Cell Transplantation in Patients with High Risk Secondary Acute Myeloblastic Leukaemia and Myelodysplastic Syndromes, Long-Term Outcomes in a Single Centre Experience.
Authors: Jean El-cheikh, Luca Castagna, Sabine Furst, Catherine Faucher, Benjamin Esterni, Patrick Ladaique, Aude Charbonier, Christian Chabannon, Norbert Vey, Didier Blaise
Journal: Blood (2009)
Expanded CD4+Foxp3+ Regulatory T Cells through DR3 Signaling Have a Distinct Immunophenotype and Abrogate the Lethal Acute-Graft and Host Disease after Allogeneic Transplantation
Authors: Hidekazu Nishikii, Byung-Su Kim, Yasuhisa Yokoyama, Jeanette Baker, Antonio Pierini, Maite Alvarez, Yuqiong Pan, Yan Chen, Dominik Schneidawind, Shigeru Chiba, Robert Negrin
Journal: Blood (2015)
Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment
Authors: Juliana Durack, Susan V. Lynch, Snehal Nariya, Nirav R. Bhakta, Avraham Beigelman, Mario Castro, Anne-Marie Dyer, Elliot Israel, Monica Kraft, Richard J. Martin, David T. Mauger, Sharon R. Rosenberg, Tonya Sharp-King, Steven R. White, Prescott G. Woodruff, Pedro C. Avila, Loren C. Denlinger, Fernando Holguin, Stephen C. Lazarus, Njira Lugogo, Wendy C. Moore, Stephen P. Peters, Loretta Que, Lewis J. Smith, Christine A. Sorkness, Michael E. Wechsler, Sally E. Wenzel, Homer A. Boushey, Yvonne J. Huang
Journal: Journal of Allergy and Clinical Immunology (2016)